Novavax, Inc.

Valneva Austria Gmbh

Valneva USA, Inc.

Intercell USA, Inc.

Jing-Hui Tian

Gale Smith

Gregory M Glenn

Michael J Massare

David Flyer

Ye Liu

Sarathi Boddapati

Kerstin Westritschnig

Steven R Fuhrmann

Larry R Ellingsworth

Stefanie Kluepfel-Stahl

Erica Shane

Cynthia Oliver

Jason Wong

Anushree Herwadkar

Yen-Huei Lin

Gregory J Glenn

Gale E Smith

Louis Fries

Iksung Cho

Gregory Glenn

Steven Fuhrmann

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains oftoxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects oftoxin A and/or toxin B.

Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine compositions having improved stability and immunogenicity

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Methods and compositions for treating respiratory disease

Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towardsinfection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Methods and compositions for inducing immune responses against

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Corona virus vaccine formulations

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Multivalent influenza nanoparticle vaccines

Coronavirus vaccine formulations

Methods and compositions for inducing immune responses against Clostridium difficile

Growing community of inventors

Germantown, MD, United States of America

Jing-Hui Tian